Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background Systemic inflammatory response syndrome (SIRS) following cardiovascular interventions is associated with adverse events during hospitalization and follow‐up. Mitral transcatheter edge‐to‐edge repair is increasingly utilized for treatment of mitral regurgitation (MR). We investigated whether SIRS following mitral transcatheter edge‐to‐edge repair may occur and be associated with adverse clinical outcomes. Methods and Results A total of 158 consecutive patients with severe MR undergoing mitral transcatheter edge‐to‐edge repair were studied. SIRS was defined by leukocytosis (≥12 × 10 9 /L) and fever (≥38 °C) within 48 hours after intervention. Baseline inflammation was measured by absolute neutrophil and lymphocyte counts and neutrophil‐lymphocyte ratio. The primary end point of major cardiovascular events was the composite of nonfatal myocardial infarction, nonfatal stroke, and all‐cause death. Recurrent MR at follow‐up was also recorded. The mean patient age was 80.8±8.8 years. Forty‐four (27.9%) developed SIRS. Neutrophil‐lymphocyte ratio correlated with onset of leukocytosis and fever ( P =0.04). During a median follow‐up of 12.5 (5.4–17.4) months, the primary end point occurred in 27 (17.1%) patients (6 myocardial infarction, 5 strokes, and 16 deaths). Patients with SIRS more often had severe MR (79.5% versus 62.7%, P =0.02) at follow‐up. After adjustment for pertinent variables, SIRS (HR 2.73 [95% CI, 1.08–6.86]; P =0.03) was independently associated with major cardiovascular events. Conclusions SIRS after mitral transcatheter edge‐to‐edge repair is a strong independent predictor of major cardiovascular events. Closer follow‐up is warranted because patients with SIRS have more severe MR at follow‐up.
Background Systemic inflammatory response syndrome (SIRS) following cardiovascular interventions is associated with adverse events during hospitalization and follow‐up. Mitral transcatheter edge‐to‐edge repair is increasingly utilized for treatment of mitral regurgitation (MR). We investigated whether SIRS following mitral transcatheter edge‐to‐edge repair may occur and be associated with adverse clinical outcomes. Methods and Results A total of 158 consecutive patients with severe MR undergoing mitral transcatheter edge‐to‐edge repair were studied. SIRS was defined by leukocytosis (≥12 × 10 9 /L) and fever (≥38 °C) within 48 hours after intervention. Baseline inflammation was measured by absolute neutrophil and lymphocyte counts and neutrophil‐lymphocyte ratio. The primary end point of major cardiovascular events was the composite of nonfatal myocardial infarction, nonfatal stroke, and all‐cause death. Recurrent MR at follow‐up was also recorded. The mean patient age was 80.8±8.8 years. Forty‐four (27.9%) developed SIRS. Neutrophil‐lymphocyte ratio correlated with onset of leukocytosis and fever ( P =0.04). During a median follow‐up of 12.5 (5.4–17.4) months, the primary end point occurred in 27 (17.1%) patients (6 myocardial infarction, 5 strokes, and 16 deaths). Patients with SIRS more often had severe MR (79.5% versus 62.7%, P =0.02) at follow‐up. After adjustment for pertinent variables, SIRS (HR 2.73 [95% CI, 1.08–6.86]; P =0.03) was independently associated with major cardiovascular events. Conclusions SIRS after mitral transcatheter edge‐to‐edge repair is a strong independent predictor of major cardiovascular events. Closer follow‐up is warranted because patients with SIRS have more severe MR at follow‐up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.